Sandostatin lar and Neoplasm recurrence - a phase IV clinical study of FDA data
Summary:
Neoplasm recurrence is reported as a side effect among people who take Sandostatin lar (octreotide acetate), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Sandostatin, and have Carcinoid tumor.
The phase IV clinical study analyzes which people have Neoplasm recurrence when taking Sandostatin lar. It is created by eHealthMe based on reports of 38,376 people who have side effects when taking Sandostatin lar from the FDA, and is updated regularly.
What is Sandostatin lar?
Sandostatin lar has active ingredients of octreotide acetate. It is often used in acromegaly. eHealthMe is studying from 38,437 Sandostatin lar users. Check the latest studies of Sandostatin lar.
What is Neoplasm recurrence?
Neoplasm recurrence (reoccurrence of tumour) is found to be associated with 357 drugs and 495 conditions by eHealthMe. Check the latest studies of Neoplasm recurrence.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
38,376 people reported to have side effects when taking Sandostatin lar.
Among them, 71 people (0.19%) have Neoplasm recurrence.

Among these 71 people:
How long have people been on Sandostatin lar when they have Neoplasm recurrence? *
- < 1 month: 0.0 %
- 1 - 6 months: 14.29 %
- 6 - 12 months: 64.29 %
- 1 - 2 years: 7.14 %
- 2 - 5 years: 14.29 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
What is the gender of people who have Neoplasm recurrence when taking Sandostatin lar? *
- female: 73.24 %
- male: 26.76 %
What is the age of people who have Neoplasm recurrence when taking Sandostatin lar? *
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 2.63 %
- 30-39: 0.0 %
- 40-49: 5.26 %
- 50-59: 21.05 %
- 60+: 71.05 %
What are other drugs people take besides Sandostatin lar? *
- Sandostatin: 21 people, 29.58%
- Indapamide: 7 people, 9.86%
- Levothyroxine Sodium: 4 people, 5.63%
- Metformin: 3 people, 4.23%
- Amlodipine: 3 people, 4.23%
- Insulin: 3 people, 4.23%
- Afinitor: 2 people, 2.82%
- Hydrochlorothiazide: 2 people, 2.82%
- Dostinex: 2 people, 2.82%
- Everolimus: 1 person, 1.41%
What are other side effects people have besides Neoplasm recurrence? *
- Nausea (feeling of having an urge to vomit): 30 people, 42.25%
- Weight Decreased: 19 people, 26.76%
- Weakness: 19 people, 26.76%
- Fatigue (feeling of tiredness): 19 people, 26.76%
- Malignant Neoplasm Progression (cancer tumour came back): 19 people, 26.76%
- Nausea And Vomiting: 18 people, 25.35%
- Joint Pain: 18 people, 25.35%
- Metastases To Liver (cancer spreads to liver): 17 people, 23.94%
- Diarrhea: 16 people, 22.54%
- High Blood Pressure: 16 people, 22.54%
What are the existing conditions these people have? *
- Carcinoid Tumor: 21 people, 29.58%
- High Blood Pressure: 17 people, 23.94%
- Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 7 people, 9.86%
- Pancreatic Neuroendocrine Tumor: 6 people, 8.45%
- Neuroendocrine Tumor: 5 people, 7.04%
- Pituitary Tumor: 5 people, 7.04%
- Diabetes: 4 people, 5.63%
- Thyroid Diseases: 2 people, 2.82%
- Blood Testosterone Abnormal: 2 people, 2.82%
- Brain Neoplasm (tumour of brain): 2 people, 2.82%
* Approximation only. Some reports may have incomplete information.
Do you take Sandostatin lar and have Neoplasm recurrence?
- Check whether Neoplasm recurrence is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Sandostatin lar:
- Sandostatin lar (38,437 reports)
Neoplasm recurrence treatments and more:
- Neoplasm recurrence (4,179 reports)
How severe was Neoplasm recurrence and when was it recovered:
Expand to all the drugs that have ingredients of octreotide acetate:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Sandostatin lar:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Neoplasm recurrence:
- Neoplasm recurrence (357 drugs)
Browse all the conditions that are associated with Neoplasm recurrence:
- Neoplasm recurrence (495 conditions)
Related publications that referenced our studies
- Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
- Azkur D, Yoldas T, Toyran M, Kocabas CN, "A pediatric case of anaphylaxis due to octreotide", Asian Pacific journal of allergy and immunology, 2011 Dec .
- Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
- Azkur D, Yoldas T, Toyran M, Kocabas CN, "A pediatric case of anaphylaxis due to octreotide", Asian Pacific journal of allergy and immunology, 2011 Dec .
How the study uses the data?
The study uses data from the FDA. It is based on octreotide acetate (the active ingredients of Sandostatin lar) and Sandostatin lar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Humira cause Oesophagitis Ulcerative? - 10 seconds ago
- Could Triumeq cause Insomnia? - 13 seconds ago
- Could Magnesium cause Nerve Root Compression? - 14 seconds ago
- Could Fluconazole cause Kidney Transplant? - 15 seconds ago
- Drug interactions of Synthroid and Vytorin - 18 seconds ago
- Osteoporosis and Confusion Aggravated - 23 seconds ago
- Could Humalog cause Bile Duct Obstruction? - 31 seconds ago
- Could Enbrel cause Csf Leak? - 34 seconds ago
- Tendonitis and Kidney Stones - 35 seconds ago
- Levocetirizine Hydrochloride vs. Loratadine, side effect and effectiveness comparison - 38 seconds ago